Share Twitter LinkedIn Facebook Email Joan Schiller, MD, shares her thoughts regarding the results of Keynote 42 presented at the 2018 Annual Meeting and how it might impact patient selection.
Targeting SCD1 in KRAS Mutant Non-Small Cell Lung Cancer: A Novel Therapeutic Strategy Non-Small Cell Lung Cancer 3 Mins Read
What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD Non-Small Cell Lung Cancer 4 Mins Read
FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] Non-Small Cell Lung Cancer 3 Mins Read